IBIO
iBio, Inc.NASDAQHealthcareAs of 2026-04-06
Valuation
View DetailsP/E (TTM)
—
PEG
—
P/B
3.56
P/S
106.84
EV/EBITDA
-0.27
DCF Value
$0.25
FCF Yield
-59.9%
Div Yield
0.0%
Margins & Returns
Gross Margin
-76.7%
Operating Margin
-7657.7%
Net Margin
-8245.7%
ROE
-71.3%
ROA
-38.4%
ROIC
-38.9%
Financials
View All| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q2 2026 | $0.00 | $-9.0M | $-0.09 |
| Q1 2026 | $100.0K | $-5.7M | $-0.11 |
| Q4 2025 | $200.0K | $-5.2M | $-0.31 |
| FY 2025 | $400.0K | $-18.4M | $-1.75 |
Analyst Ratings
View AllTrading Activity
Insider Trades
View AllCompany Info
Sector
Healthcare
Industry
—
Country
US
Exchange
NASDAQ
Beta
1.36
iBio, Inc., a biotechnology company, provides contract development and manufacturing services to collaborators and third-party customers in the United States. The company operates in two segments: Biopharmaceuticals and Bioprocessing. Its lead therapeutic candidate is IBIO-100 that is being advanced for investigational new drug development for the treatment of systemic scleroderma and idiopathic pulmonary fibrosis. The company is also developing vaccine candidates comprising IBIO-200 and IBIO-201, which are in preclinical development for the prevention of severe acute respiratory syndrome coronavirus 2; and IBIO-400 for the treatment of classical swine fever. In addition, it is developing recombinant proteins for third parties on a catalog and custom basis; and offers a range of process development, manufacturing, filling and finishing, and bio analytic services. iBio, Inc. has a license agreement with Planet Biotechnology, Inc. to develop therapeutics for infectious diseases; collaboration agreement with The Texas A&M University System for the development of coronavirus disease 2019 vaccine candidates; license agreement with the University of Natural Resources and Life Sciences, Vienna; and collaboration agreement with CC-Pharming Ltd. The company is headquartered in Bryan, Texas.